Thèse Amandine Martin - EPHE
Thèse Amandine Martin - EPHE Thèse Amandine Martin - EPHE
96. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of immunology (Baltimore, Md. : 1950) 166, 678-89(2001). 97. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NOdependent mechanism. Journal of immunology 168, 689-95(2002). 98. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature reviews. Immunology 5, 641-54(2005). 99. Rodríguez, P.C. & Ochoa, A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological reviews 222, 180-91(2008). 100. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. The Journal of clinical investigation 117, 1155-66(2007). 101. Bogdan, C. Nitric oxide and the immune response. Nature immunology 2, 907- 16(2001). 102. Bronte, V. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumorbearing mice. Journal of immunology 170, 270-8(2003). 103. Li, H. et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. Journal of immunology 182, 240-9(2009). 104. Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr- 1+CD11b+ myeloid cells that promote metastasis. Cancer cell 13, 23-35(2008). 105. Pan, P.-Y. et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer research 70, 99-108(2010). 106. Serafini, P. et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer research 68, 5439-49(2008). 107. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of immunology (Baltimore, Md. : 1950) 182, 4499- 506(2009). 108. Mellman, I., Steinman, R.M. & Haven, N. Dendritic Cells : Specialized and Regulated Antigen Minireview. 106, 255-258(2001). 109. Banchereau, J. et al. Imunobiology of dendritic cells. Immunology 767-811(2000). 110. Waldmann, T.A. Immunotherapy: past, present and future. Nature medicine 9, 269- 77(2003). 42
111. Herr, H.W. et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 6, 1450-5(1988). 112. Alexandroff, A.B. et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353, 1689-94(1999). 113. Lamm, D.L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology 163, 1124-9(2000). 114. Janeway, C.A. How the immune system protects the host from infection. Microbes and infection / Institut Pasteur 3, 1167-71(2001). 115. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nature reviews. Cancer 4, 11-22(2004). 116. Fosså, S.D., Kramar, A. & Droz, J.P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. European journal of cancer (Oxford, England : 1990) 30A, 1310-4(1994). 117. Kirkwood, J.M., Resnick, G.D. & Cole, B.F. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Seminars in oncology 24, S16-23(1997). 118. Kirkwood, J. Cancer immunotherapy: the interferon-alpha experience. Seminars in oncology 29, 18-26(2002). 119. Dutcher, J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park, N.Y.) 16, 4-10(2002). 120. Taneja, S.S. et al. Immunotherapy for renal cell carcinoma: the era of interleukin-2based treatment. Urology 45, 911-24(1995). 121. Negrier, S. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français dʼImmunothérapie. The New England journal of medicine 338, 1272-8(1998). 122. Trinchieri, G. & Scott, P. Interleukin-12: basic principles and clinical applications. Current topics in microbiology and immunology 238, 57-78(1999). 123. Younes, A. et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkinʼs lymphoma and Hodgkin's disease. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 5432-8(2004). 124. Erridge, C., Bennett-Guerrero, E. & Poxton, I.R. Structure and function of lipopolysaccharides. Microbes and infection / Institut Pasteur 4, 837-51(2002). 125. Coley, W.B. The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and Bacillus prodigious. J. Am. Med. Assoc 31, 389-395(1898). 43
- Page 1 and 2: UNIVERSITÉ DE BOURGOGNE & ÉCOLE P
- Page 3 and 4: Liste des abréviations Liste des f
- Page 5 and 6: 5-FU: 5-Fluorouracile A LISTE DES A
- Page 7 and 8: GPI: glycosylphosphatidylinositol G
- Page 9 and 10: NaCl: Chlorure de sodium NaNO2: Sod
- Page 11 and 12: I. Le cancer colorectal A. Généra
- Page 13 and 14: cérébrales 16 chez des patients.
- Page 15 and 16: ganglionnaires, hépatiques ou pulm
- Page 17 and 18: limitantes. Le risque d'alopécie e
- Page 19 and 20: hémorragique ou de l’ischémie :
- Page 21 and 22: 3. Les cellules du système immunit
- Page 23 and 24: chimiotactisme, les neutrophiles so
- Page 25 and 26: c) Les cellules Natural Killer Il s
- Page 27 and 28: phagocytaire faible, la capacité d
- Page 29 and 30: ‐ La chaîne O‐spécifique est
- Page 31 and 32: cellules phagocytaires (inhibition
- Page 33 and 34: différentes cytokines vont activer
- Page 35 and 36: Ces données ont été suffisamment
- Page 37 and 38: 18. Kelly, P.N. et al. Tumor growth
- Page 39 and 40: 49. Jeannin, P., Jaillon, S. & Deln
- Page 41: 80. Jakóbisiak, M., Lasek, W. & Go
- Page 45 and 46: 140. Takai, N. et al. Primary struc
- Page 47 and 48: 167. Feist, W. et al. Induction of
- Page 49 and 50: 193. Fridlender, Z.G. et al. Polari
- Page 51 and 52: 222. Ishikawa, F. & Miyazaki, S. Ne
96. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a<br />
mechanism of immunosuppression in cancer. Journal of immunology (Baltimore, Md. :<br />
1950) 166, 678-89(2001).<br />
97. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NOdependent<br />
mechanism. Journal of immunology 168, 689-95(2002).<br />
98. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism.<br />
Nature reviews. Immunology 5, 641-54(2005).<br />
99. Rodríguez, P.C. & Ochoa, A.C. Arginine regulation by myeloid derived suppressor<br />
cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological<br />
reviews 222, 180-91(2008).<br />
100. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in<br />
tumor development. The Journal of clinical investigation 117, 1155-66(2007).<br />
101. Bogdan, C. Nitric oxide and the immune response. Nature immunology 2, 907-<br />
16(2001).<br />
102. Bronte, V. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumorbearing<br />
mice. Journal of immunology 170, 270-8(2003).<br />
103. Li, H. et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK<br />
cells through membrane-bound TGF-beta 1. Journal of immunology 182, 240-9(2009).<br />
104. Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-<br />
1+CD11b+ myeloid cells that promote metastasis. Cancer cell 13, 23-35(2008).<br />
105. Pan, P.-Y. et al. Immune stimulatory receptor CD40 is required for T-cell suppression<br />
and T regulatory cell activation mediated by myeloid-derived suppressor cells in<br />
cancer. Cancer research 70, 99-108(2010).<br />
106. Serafini, P. et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell<br />
lymphoma by expanding regulatory T cells. Cancer research 68, 5439-49(2008).<br />
107. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking<br />
inflammation and cancer. Journal of immunology (Baltimore, Md. : 1950) 182, 4499-<br />
506(2009).<br />
108. Mellman, I., Steinman, R.M. & Haven, N. Dendritic Cells : Specialized and Regulated<br />
Antigen Minireview. 106, 255-258(2001).<br />
109. Banchereau, J. et al. Imunobiology of dendritic cells. Immunology 767-811(2000).<br />
110. Waldmann, T.A. Immunotherapy: past, present and future. Nature medicine 9, 269-<br />
77(2003).<br />
42
Change language